Posted by Michael Wonder on 20 Jul 2024
EMA accepts Deciphera’s marketing authorisation application for vimseltinib for treatment of patients with tenosynovial giant cell tumour
18 July 2024 - Application based on results from the MOTION Phase 3 study, in which vimseltinib demonstrated statistically significant and clinically meaningful improvement in objective response rate compared to placebo.
Ono Pharmaceutical today announced that the EMA has accepted the marketing authorisation application for vimseltinib, a colony stimulating factor 1 receptor, for the treatment of patients with tenosynovial giant cell tumour which is under development by Deciphera Pharmaceuticals, a wholly owned subsidiary of Ono.
